A Phase 2 interventional study of Fenfluramine in Infantile Spasm, sponsored by Children's Hospital of Orange County. Recruiting at 2 sites in United States. Open to participants aged 12 Months to 36 Months. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by Children's Hospital of Orange County · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Spasms, Infantile with a site in United States — 2 open to participants now, 3 under way, 1 of them phase 3. Spasms, Infantile · United States.
Among the 22 studies in Spasms, Infantile with a site in United States, this one is the 9th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2023, is one of 7 in phase 2, and was the 16th registered.
47 studies on the registry are indexed under Spasms, Infantile; 8 are open to participants now.
Browse Spasms, Infantile studies →2 of the 22 studies in Spasms, Infantile with a site in United States are open now. Recruiting first, the newest first:
University of California, Los Angeles · Sites in United States
Ages 2 mo–18 mo
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Spasms, Infantile studies recruiting now, none set no upper age limit and 8 stop at 75 or younger; 8 take children under 18; none take healthy volunteers.
This study: 12 Months to 36 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 1992; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 40 across 33 interventional studies indexed under Spasms, Infantile.
Median enrollment 10 across the 18 interventional studies, 72 across the 4 observational. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 22 have an industry lead sponsor. The 10 most frequent:
Children's Hospital of Orange County is the lead sponsor of 19 studies on the registry; 11 are open to participants now.
Children's Hospital of Orange County has 1 study filed under Spasms, Infantile — fewer than ten, so there is no comparison to draw.
2 of the studies in Spasms, Infantile with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05064878Phase 3Zogenix, Inc.A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder. | 2027-11-08 |
| NCT04289467Children's Hospital of Orange CountyTreatment of Refractory Infantile Spasms With Fenfluramine | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies in Spasms, Infantile with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase II clinical trial in which children with refractory infantile spasms (also called epileptic spasms or West syndrome) will be treated with fenfluramine, to evaluate efficacy, safety, and tolerability. Patients with infantile spasms that have not responded to treatment with vigabatrin and ACTH we will be invited to participate. Study participants will undergo baseline video-EEG, receive treatment with fenfluramine for 21 days, and then undergo repeat video-EEG to determine effectiveness. Patients with favorable response will have the opportunity to continue treatment for up to 6 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open label treatment with fenfluramine. Dosage will be titrated to 0.8 mg/kg/day, for an initial duration of 21 days. Patients with favorable response will have an option to continue treatment for up to 6 months.
Drug: Fenfluramine
Open-label
Also known as: Fenfluramine Hydrochloride
Electroclinical response (Efficacy)
Number of participants with resolution of epileptic spasms and hypsarrhythmia (if present at baseline) after 21 days of treatment, as determined by overnight video-electroencephalography (EEG) evaluation and caregiver seizure diary.
Time frame: 12 months
Computational electroencephalography response (Efficacy)
Median and range of response quantified using the probability-weighted response index (PWRI), a novel computational electroencephalography measure of hypsarrhythmia burden.
Time frame: 12 months
Incidence of treatment emergent adverse events (Safety and tolerability)
Detailed accounting of all treatment-emergent adverse events, including number of participants with clinically-significant valvulopathy and/or pulmonary hypertension, as determined by echocardiography.
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for Dec 2026, 42 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fenfluramine
Children's Hospital of Orange County